IRVINE, Calif., May 21, 2017 -- Pain Management Center of Irvine recently released information on the superiority of SurForce® compared to prolotherapy or PRP. Unlike the alternatives, which take hours per appointment, SurForce® only requires 15 minutes per session. SurForce® is also painless, while the other two options can be painful. The SurForce® treatments also promote healing rather than only managing pain.
Prolotherapy is an older treatment method that involves injecting dextrose into painful tissues to intentionally cause an inflammatory response. The underlying belief is that it will cause the body to speed healing in the inflamed area as well as the injured part. In practice, however, it is used to manage pain instead of to regenerate tissue. Unfortunately, the inflammation it brings on actually causes pain for the duration of the treatments.
Platelet Rich Plasma (PRP) is a stem cell therapy made up of blood, bone marrow, and fat (adipose) tissue. Getting these ingredients involves sucking bone marrow and fat out of the patient's body, and this is said to be a very painful process. It is even worse for older patients since they have fewer viable stem cells and need to donate more tissue to make up for this.
"It is clear that these older methods each have significant shortcomings. This is why we decided to implement the SurForce® system instead. SurForce® combines amniotic membrane tissue, biological scaffolding, and hyaluronic acid to provide a strong healing boost to painful areas via the addition of stem cells. This not only relieves pain, but allows the body to heal faster. Even better, this treatment is delivered by a painless injection," explained Dr. Rick Letts of Pain Management Center of Irvine.
Many people have questions when they learn that amniotic membrane is part of the SurForce® treatment. Specifically, they want to know where it comes from. There is no need for concern over this aspect of SurForce®. The FDA regulated amniotic membrane is voluntarily donated by women who have had cesarean deliveries.
Like many other healing treatments, SurForce® takes several weeks to fully implant in a patient, which is when the most noticeable improvement to their condition can be observed. Therefore, patients are advised to stick to light activity for the first few weeks. This ensures that everything will heal properly and prevent further injury during the course of treatment.
About Pain Management Center of Irvine
The Center offers a wide variety of pain management treatments, ranging from advanced stem cell therapy all the way to traditional healing methods like acupuncture and cupping. It serves the area of Irvine, CA.
To learn more about SurForce®, visit the Pain Management Center of Irvine’s website at http://chirocenterofirvine.com/.
Pain Management Center of Irvine 4902 Irvine Center Dr. #201 Irvine, CA 92604 (949) 857-4712


Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 



